Research ArticleHEALTH AND MEDICINE

Targeted delivery of antisense oligonucleotides to pancreatic β-cells

See allHide authors and affiliations

Science Advances  17 Oct 2018:
Vol. 4, no. 10, eaat3386
DOI: 10.1126/sciadv.aat3386

Article Information

vol. 4 no. 10

Online ISSN: 
History: 
  • Received for publication February 15, 2018
  • Accepted for publication September 12, 2018
  • .

Author Information

  1. C. Ämmälä1,*,
  2. W. J. Drury III1,
  3. L. Knerr1,
  4. I. Ahlstedt1,
  5. P. Stillemark-Billton1,
  6. C. Wennberg-Huldt1,
  7. E.-M. Andersson1,
  8. E. Valeur1,
  9. R. Jansson-Löfmark1,
  10. D. Janzén1,
  11. L. Sundström2,
  12. J. Meuller2,
  13. J. Claesson2,
  14. P. Andersson3,
  15. C. Johansson3,
  16. R. G. Lee4,
  17. T. P. Prakash4,
  18. P. P. Seth4,*,
  19. B. P. Monia4 and
  20. S. Andersson1
  1. 1Cardiovascular Renal and Metabolic Diseases, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
  2. 2Discovery Sciences, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
  3. 3Drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
  4. 4Ionis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, CA 92010, USA.
  1. *Corresponding author. Email: carina.ammala{at}astrazeneca.com (C.Ä.); pseth{at}ionisph.com (P.P.S.)

Altmetric

Article usage

Article usage: October 2018 to September 2019

AbstractFullPdf
Oct 2018042101259
Nov 201801100407
Dec 20180641179
Jan 20191531134
Feb 201921337109
Mar 20197337120
Apr 20198431101
May 20195403117
Jun 2019429486
Jul 20196355182
Aug 20192325110
Sep 2019016758

Navigate This Article